[Author Disclosure: This content reflects the views of the author and is provided for informational purposes only. It does not constitute investment advice and is not a recommendation or endorsement by BioTech Funding Portal. Any investment decision should be based solely on the issuer’s official offering materials.]
The main recognized risks of lentiviral HSC gene therapy are (1) insertional risk: the vector integrates into the genome, and in rare cases in the wider field, integration has been linked to abnormal cell growth; (2) conditioning risk: the chemotherapy used to make room for corrected cells carries its own side effects; and (3) procedure risk from stem cell collection and re-infusion. In FACTS, insertion-site analysis of all five patients showed a polyclonal profile with no clonal dominance, and there were zero product-attributable serious adverse events. Conditioning was non-myeloablative (melphalan-based), and 4 of 5 patients went home the same day.
Interpretation: The FACTS safety profile is encouraging, and the gentler conditioning regimen was a deliberate design choice to lower risk and burden.
Uncertainty: Five patients is a small safety database. Rare events may not show up until more patients are treated and followed for longer, which is why long-term monitoring is built into gene therapy development.
Safety questions are welcome below; we'd rather answer them in public.
Follow the whole series: https://bit.ly/Glafabra-TTW
@Brian Christie @Neva West @Chris Hopkins @Tetsu Yung
Testing the Waters disclosure: We are considering a capital raise and are "Testing the Waters" under Regulation Crowdfunding. No money or other consideration is being solicited, and any that is sent in response will not be accepted. We cannot accept any offer to buy securities, and no part of the purchase price can be received until an offering statement is filed and only through the BioTech Funding Portal platform. Any indication of interest is non-binding and involves no obligation or commitment of any kind.
Register for FREE to comment or continue reading this article. Already registered? Login here.
0